TY - JOUR
T1 - A cluster of acute thebaine poisonings from non-food grade poppy seeds in the Australian food supply
AU - Isoardi, Katherine Z.
AU - Roberts, Darren M.
AU - Holford, Amanda G.
AU - Brown, Jared A.
AU - Griffiths, Andrew
AU - Soderstrom, Jessamine
AU - McDonald, Catherine
AU - Gerostamoulos, Dimitri
AU - Sakrajda, Paul
AU - Turner, Claire
AU - Yates, Hans
AU - Gunja, Naren
AU - Greene, Shaun
N1 - Funding Information:
The EDNA collaboration is supported by an NHMRC Ideas Grant (GNT2001107). The study group would like to acknowledge the following people:NSW Health clinical and analytical collaborators through PRISE: Ingrid Berling, Sean Kelly, David Yoo, Rowena Penafiel, Andrew Dawson, Nick Buckley, Kirsty Hope, Una Nic Ionmhain, Betty Chan, Lucy Kuehn, Amy Thomson, Dushan Jayaweera, Jason Tran, Vanessa Shaw and Keira Glasgow and Health Protection NSW WA Public health (Communicable Disease Control Directorate): Jelena Maticevic and Rebecca Hogan SEATs Clinicians: Ben Weber and Andrew Kozman Queensland Health (Metro South and Sunshine Coast Public Health Units) and the Forensic and Scientific Services Organic Chemistry team Health.Vic clinical, analytical, and public health collaborators: Danny Csutoros, Aoife Hurley, Rebekka Syrjanen, Jennifer Schumann, Sarah Hodgson, Rachelle Abouchedid and Jared Castle.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Poppy seed tea is used for its opioid effects and contains multiple opium alkaloids, including morphine, codeine, papaverine, and thebaine. Animal studies indicate thebaine has strychnine-like properties, but there is limited literature describing human thebaine poisoning. We describe a cluster of acute thebaine poisoning in people ingesting tea made using poppy seeds with high thebaine content that entered the Australian food supply chain. Methods: This is an observational study of patients poisoned after drinking poppy seed tea. Cases were identified by three prospective toxicovigilance systems: the Emerging Drug Network of Australia collaboration, the New South Wales Prescription, Recreational and Illicit Substance Evaluation program, and the Emerging Drugs Network of Australia Victoria study. We report characteristics of clinical toxicity in cases with reported ingestion of poppy seed tea and analytical confirmation of thebaine exposure. Results: Forty cases presenting with multi-system toxicity following poppy seed tea ingestion were identified across seven Australian states/territories from November 2022 to January 2023. Blood testing in 23 cases confirmed high thebaine concentrations. All 23 were male (median age 35, range 16–71 years). All patients experienced muscle spasms. Rigidity was described in nine, convulsions in six, while rhabdomyolysis, acute kidney injury, and metabolic acidosis occurred in five patients. There were two cardiac arrests. The thebaine median admission blood concentration was 1.6 mg/L, with a range of 0.1–5.6 mg/L, and was the dominant opium alkaloid in all samples. Convulsions, acute kidney injury, metabolic acidosis, and cardiac arrest were associated with increasing median thebaine concentrations. Four patients were managed in the Intensive Care Unit, with two receiving continuous kidney replacement therapy (one also received intermittent haemodialysis) for kidney injury. There was one death. Conclusions: Thebaine toxicity, like strychnine poisoning, resulted in neuromuscular excitation characterized by muscle spasm, rigidity, and convulsions. Severe toxicity, including acute kidney injury, metabolic acidosis, and cardiac arrest, appears dose-dependent.
AB - Introduction: Poppy seed tea is used for its opioid effects and contains multiple opium alkaloids, including morphine, codeine, papaverine, and thebaine. Animal studies indicate thebaine has strychnine-like properties, but there is limited literature describing human thebaine poisoning. We describe a cluster of acute thebaine poisoning in people ingesting tea made using poppy seeds with high thebaine content that entered the Australian food supply chain. Methods: This is an observational study of patients poisoned after drinking poppy seed tea. Cases were identified by three prospective toxicovigilance systems: the Emerging Drug Network of Australia collaboration, the New South Wales Prescription, Recreational and Illicit Substance Evaluation program, and the Emerging Drugs Network of Australia Victoria study. We report characteristics of clinical toxicity in cases with reported ingestion of poppy seed tea and analytical confirmation of thebaine exposure. Results: Forty cases presenting with multi-system toxicity following poppy seed tea ingestion were identified across seven Australian states/territories from November 2022 to January 2023. Blood testing in 23 cases confirmed high thebaine concentrations. All 23 were male (median age 35, range 16–71 years). All patients experienced muscle spasms. Rigidity was described in nine, convulsions in six, while rhabdomyolysis, acute kidney injury, and metabolic acidosis occurred in five patients. There were two cardiac arrests. The thebaine median admission blood concentration was 1.6 mg/L, with a range of 0.1–5.6 mg/L, and was the dominant opium alkaloid in all samples. Convulsions, acute kidney injury, metabolic acidosis, and cardiac arrest were associated with increasing median thebaine concentrations. Four patients were managed in the Intensive Care Unit, with two receiving continuous kidney replacement therapy (one also received intermittent haemodialysis) for kidney injury. There was one death. Conclusions: Thebaine toxicity, like strychnine poisoning, resulted in neuromuscular excitation characterized by muscle spasm, rigidity, and convulsions. Severe toxicity, including acute kidney injury, metabolic acidosis, and cardiac arrest, appears dose-dependent.
KW - opioid
KW - Poisoning
KW - poppy seed
KW - thebaine
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=85174238476&partnerID=8YFLogxK
U2 - 10.1080/15563650.2023.2265053
DO - 10.1080/15563650.2023.2265053
M3 - Article
C2 - 37855308
AN - SCOPUS:85174238476
SN - 1556-3650
VL - 61
SP - 639
EP - 643
JO - Clinical Toxicology
JF - Clinical Toxicology
IS - 9
ER -